SEPREHVEC - A TECHNOLOGY PLATFORM
SEPREHVIR is the first in a series of oncolytic immunotherapies engineered by VIRTTU that have significant therapeutic potential.
VIRTTU has also developed a proprietary platform (SEPREHVEC) which aims to provide additional therapeutic options and can rapidly generate novel oncolytic immunotherapies that are:
- "targeted" specifically to tumour cells; and/or
- "armed" with additional genes to enhance the destruction of tumour cells
- multi-functional"targeted" and "armed" variants with enhanced cell killing and immuno-stimulatory activities.
We are conducting clinical studies in a wide range of cancer types in leading medical centres in the USA and Europe.